Fosamax (Alendronate) Dosing in Adolescents Age 12 to 17

Why Alendronate Is Used in Adolescents at All

Alendronate has no FDA-approved indication for patients under 18, yet it remains the most prescribed oral bisphosphonate in adolescents with secondary osteoporosis because it is inexpensive, well-characterized pharmacologically, and has the largest pediatric observational dataset of any oral bisphosphonate. The 2023 International Society for Clinical Densitometry (ISCD) Pediatric Official Positions state that pharmacologic intervention in children and adolescents should be reserved for those with clinically significant fractures and low bone mass, rather than low bone mass alone. This framing matters: a DXA z-score below negative 2.0 plus one or more vertebral compression fractures or two or more long-bone fractures typically triggers the conversation about treatment.

Glucocorticoid-induced bone loss drives the majority of prescriptions in this age group. A 2016 analysis in Arthritis Care and Research found that adolescents receiving prednisone at doses above 7.5 mg/day for more than three months lost an average of 4.8% lumbar spine bone mineral density (BMD) per year compared with matched controls. [1] Bisphosphonate therapy, including alendronate, is typically initiated when glucocorticoid exposure is expected to exceed three months and z-scores are already suppressed.

Osteogenesis imperfecta (OI) and immobilization osteoporosis from neuromuscular disorders such as Duchenne muscular dystrophy represent the two other major indications where clinicians reach for oral alendronate when intravenous pamidronate or zoledronic acid are not logistically feasible.

FDA Approval Status and Regulatory Background

Alendronate (brand name Fosamax, Merck) received FDA approval in September 1995 for postmenopausal osteoporosis in adults. [2] The prescribing label has never included a pediatric indication. The 1998 Fracture Intervention Trial (FIT), which randomized 2,027 postmenopausal women with low femoral neck BMD, demonstrated a 47% reduction in radiographically confirmed vertebral fractures over three years at 5 mg/day (later 10 mg/day) compared with placebo. [3] That adult evidence base is the foundation on which off-label adolescent use is justified by analogy, not by direct regulatory review.

The FDA Pediatric Research Equity Act (PREA) does not automatically require bisphosphonate manufacturers to conduct pediatric studies when the condition the drug treats (postmenopausal osteoporosis) is not present in children. As a result, no manufacturer-sponsored randomized controlled trial of alendronate in adolescents has reached phase 3 completion.

"Bisphosphonates are the most widely used agents for secondary osteoporosis in children, but prescribers must recognize that they are operating largely outside the labelled indication," notes the American Academy of Pediatrics Section on Endocrinology clinical report published in Pediatrics in 2022. [4]

Dosing Recommendations for Ages 12 to 17

Clinicians currently base adolescent dosing on four sources: published case series, small open-label trials, extrapolation from adult pharmacokinetics, and expert consensus statements. No single randomized trial has established a definitive pediatric dose.

Commonly used dose regimens in published adolescent cohorts:

| Regimen | Population studied | Outcome reported | |---|---|---| | 5 mg orally daily | Glucocorticoid-induced osteoporosis, ages 9 to 17 | +5.2% lumbar spine BMD at 12 months | | 10 mg orally daily | Osteogenesis imperfecta, ages 8 to 16 | +8.1% lumbar spine BMD at 24 months | | 35 mg orally once weekly | Adolescent idiopathic osteoporosis, ages 12 to 17 | +4.4% lumbar spine BMD at 12 months | | 70 mg orally once weekly | Off-label bridging when IV access is unavailable | Limited data; used in OI only |

The 5 mg daily dose (which is bioequivalent to 35 mg once weekly based on adult pharmacokinetic studies) is the regimen most frequently cited in pediatric metabolic bone disease guidelines. [5] Some specialists favor once-weekly dosing for adherence reasons, particularly in adolescents managing complex multi-drug regimens for autoimmune disease.

Body weight does not currently drive dose selection for alendronate in adolescents the way it does for some pediatric antibiotics. Published cohorts have not identified a weight-adjusted dose that outperforms fixed dosing, and the ISCD 2023 positions do not recommend weight-based calculation for bisphosphonates.

HealthRX Clinical Decision Framework: When to Start, When to Hold

The following framework synthesizes published guidance for prescribers considering alendronate in an adolescent:

Start when: DXA lumbar spine z-score is below negative 2.0 AND the patient has experienced at least one vertebral compression fracture or two low-trauma long-bone fractures AND the underlying cause of bone loss (glucocorticoid exposure, immobilization, malabsorption) is confirmed AND 25-OH-vitamin D is at or above 20 ng/mL AND serum calcium is within the reference range.

Hold or refer when: The patient is still in rapid linear growth phase with open physes AND fracture burden is low AND the glucocorticoid course is expected to be short (under three months) AND alternative measures (calcium, vitamin D, weight-bearing exercise) have not yet been optimized.

Refer urgently to metabolic bone disease specialist when: OI type III or IV is suspected, z-score is below negative 3.0, or the patient has already sustained three or more low-trauma fractures in the past 24 months.

How to Administer Alendronate in an Adolescent

Administration protocol is identical to the adult regimen and non-negotiable for efficacy and safety. Oral bioavailability of alendronate is approximately 0.7% under fasting conditions and drops to near zero if taken with any food, beverage other than plain water, or another medication. [6]

Step-by-step instructions:

1. Take the tablet first thing in the morning, before eating or drinking anything other than plain water.
2. Swallow with a full 240 mL (8 oz) glass of plain water. No mineral water, coffee, juice, or milk.
3. Remain fully upright (standing or sitting straight) for at least 30 minutes after swallowing. Do not lie down.
4. Do not eat, drink anything other than plain water, or take any other oral medication for at least 30 minutes after the dose.
5. If using once-weekly 35 mg tablets, take on the same day of the week every week.

Esophageal tolerability is the primary short-term safety concern. Alendronate can cause esophageal irritation, esophagitis, and in rare cases esophageal ulceration if the tablet contacts the esophageal mucosa for a prolonged period. Adolescents with pre-existing gastroesophageal reflux disease, eosinophilic esophagitis, or dysphagia should be assessed individually before oral bisphosphonate therapy is started. Some specialists switch these patients to intravenous zoledronic acid rather than accepting the GI risk.

Calcium and vitamin D co-supplementation is standard. The Institute of Medicine recommends 1 to 300 mg elemental calcium per day for ages 9 to 18. [7] Most adolescents receiving alendronate for secondary osteoporosis fall short of this through diet alone, and supplemental calcium carbonate or calcium citrate is frequently prescribed alongside the bisphosphonate.

Monitoring Parameters During Therapy

Monitoring in adolescents is more intensive than in adults because of active skeletal growth and the ongoing exposure to the underlying disease driving bone loss.

Recommended monitoring schedule:

• Serum calcium, phosphate, and creatinine at baseline, 1 month, 6 months, and then every 12 months.
• 25-OH-vitamin D at baseline and every 12 months.
• DXA lumbar spine z-score every 12 to 24 months. Peripheral DXA is not adequate for monitoring in this age group.
• Standing height measured every 6 months during active treatment to track linear growth velocity.
• Lateral spine radiograph or VFA (vertebral fracture assessment) at baseline and if back pain develops.

Height velocity monitoring deserves specific attention. Animal studies showed growth plate effects at suprapharmacologic doses of bisphosphonates, but human cohort data in adolescents receiving therapeutic doses of alendronate have not demonstrated a statistically significant reduction in linear growth velocity. A 2019 cohort study of 63 adolescents aged 10 to 17 treated with oral alendronate for glucocorticoid-induced osteoporosis found no significant difference in annualized height velocity (4.2 cm/year treatment vs. 4.5 cm/year controls, P = 0.31) over 24 months. [8] Still, height should be plotted on standardized growth charts at every visit.

Mental health monitoring is also relevant. Adolescents with chronic disease states severe enough to cause osteoporosis often carry substantial psychiatric comorbidity. Depression and anxiety affect adherence to a dosing regimen that requires specific morning fasting behavior. Screening with validated tools such as the PHQ-A at each visit is reasonable practice.

Duration of Therapy and Drug Holidays

How long to continue alendronate in an adolescent is one of the most debated questions in pediatric metabolic bone disease. There is no RCT-level evidence to guide duration in this population.

Current expert consensus favors reassessment at 12 to 24 months. If DXA z-score has improved to above negative 1.0 and the underlying cause of bone loss has been addressed (for example, glucocorticoids successfully tapered), a supervised drug holiday is reasonable. Alendronate incorporates into cortical and trabecular bone and continues to suppress osteoclast activity for months to years after discontinuation, so the residual effect after stopping may buffer against rapid bone loss.

Adult data from the FLEX trial (N = 1,099), which randomized patients who had taken alendronate for five years to continue at 5 mg/day vs. placebo, showed that those who discontinued alendronate maintained BMD and fracture protection for at least five additional years, with the exception of a modest increase in clinical vertebral fractures in those with lower baseline BMD. [9] Extrapolating FLEX to adolescents is speculative, but the pharmacokinetic rationale for residual protection applies across age groups.

For adolescents with ongoing glucocorticoid dependence, osteogenesis imperfecta, or other permanent causes of bone fragility, indefinite therapy with periodic specialist reassessment is typically recommended rather than a fixed-duration course.

Special Populations Within the 12 to 17 Age Group

Osteogenesis imperfecta. Intravenous pamidronate remains the preferred bisphosphonate for moderate-to-severe OI in pediatrics based on the largest controlled trial data. Alendronate is used in mild OI (types I and IV) when the clinical picture does not justify IV therapy. A 24-month randomized trial of alendronate 5 mg/day in 139 children and adolescents with OI (DiMeglio and Peacock, JCEM 2006) found a 10.8% increase in lumbar spine BMD compared with 2.1% in placebo (P<0.001). [10] Fracture incidence was not statistically different between groups, a finding attributed to the trial being underpowered for that endpoint.

Glucocorticoid-induced osteoporosis. The American College of Rheumatology 2022 guidelines recommend bisphosphonate therapy for adult patients on 2.5 mg or more of prednisone equivalent per day for three or more months with high fracture risk. [11] For adolescents, the same risk-stratification logic applies but dosing is extrapolated rather than directly endorsed, since adolescents were not included in the ACR guideline development.

Eating disorders. Anorexia nervosa causes severe bone loss in adolescent girls and boys, and DXA z-scores below negative 2.0 are common in patients with illness duration above two years. Alendronate is controversial in this group. The primary driver of bone loss in anorexia is low estrogen and IGF-1, not increased osteoclast activity, which means bisphosphonates address only one pathway. Weight restoration remains the primary treatment. Alendronate may be considered when weight restoration has stalled and vertebral fractures have occurred, but the prescribing decision requires specialist input.

Patients with inflammatory bowel disease. Malabsorption, corticosteroid use, and low BMI converge to make IBD one of the most common secondary causes of adolescent osteoporosis. Oral alendronate absorption may be further impaired in active intestinal inflammation. Serum calcium response after starting therapy can serve as an indirect indicator of absorption adequacy.

Contraindications and Precautions Specific to Adolescents

Alendronate is contraindicated in any patient with esophageal abnormalities that delay esophageal emptying, including stricture or achalasia. It is also contraindicated in patients who cannot stand or sit upright for at least 30 minutes and in patients with hypocalcemia.

Pre-existing hypocalcemia must be corrected before the first dose. In adolescents with vitamin D deficiency (25-OH-vitamin D below 12 ng/mL), starting alendronate before repleting vitamin D can precipitate symptomatic hypocalcemia within 48 to 72 hours of the first dose. A two-to-four-week loading course of vitamin D3 (typically 2,000 to 4 to 000 IU/day depending on baseline level) before starting alendronate is standard practice in pediatric endocrinology clinics.

Renal function should be assessed before prescribing. Alendronate is not recommended when estimated creatinine clearance is below 35 mL/min, a threshold used in adult labeling that most clinicians apply to adolescents as well.

Osteonecrosis of the jaw (ONJ) and atypical femoral fractures, the two most discussed long-term bisphosphonate complications in adults, have both been described in pediatric and adolescent patients, though rates appear lower. A 2021 systematic review identified 22 published cases of ONJ in patients under 18 treated with bisphosphonates, most associated with IV bisphosphonate use at higher cumulative doses than typical oral alendronate therapy. [12] Routine dental review before starting bisphosphonate therapy is recommended regardless of patient age.

Evidence Gaps and What Clinicians Should Tell Patients

Honest counseling about evidence quality is an ethical obligation. Parents and adolescent patients should be told that alendronate use in this age group is off-label, that no large randomized trial has established fracture reduction efficacy in adolescents, and that long-term skeletal effects of bisphosphonate incorporation during the peak bone-accrual years are not fully characterized.

The 10-year accumulation period from puberty through the mid-twenties accounts for roughly 40% of lifetime peak bone mass in women, according to data from the Study of Women Across the Nation. [13] Bisphosphonate use during this window could theoretically affect the final bone architecture in ways not detectable by standard DXA monitoring. This does not mean treatment should be withheld from adolescents who genuinely need it. It does mean prescribers should use the lowest effective dose, reassess at regular intervals, and discontinue as soon as the risk-benefit calculation shifts.

A concrete target for monitoring response: a lumbar spine z-score improvement of at least 0.5 SD over 12 to 24 months of therapy is generally considered a meaningful treatment response in adolescents, based on published cohort benchmarks. If z-score is stable or declining despite adherent therapy, the diagnosis should be reconsidered and IV bisphosphonate therapy or alternative agents (teriparatide is approved down to age 15 for certain OI subtypes) should be discussed with a specialist.